Thanks to a new three-in-one blood test, AstraZeneca’s drug Lynparza could be transformed into precision medicine for patients with prostate cancer, researchers said. On Monday, June 19, a newly published study revealed how a blood test that analyzes cancer DNA from patients can revolutionize prostate cancer treatment. AstraZeneca’s Lynparza has long been approved for the treatment...